Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Monsenso ASOCSE:MONSO +4.57%29 PEG Ratio is 0.00 as of Jul. 13, 2026. GuruFocus rates OCSE:MONSO with a GF Score™ of 29/100 and a GF Value™ of kr0.15 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 224 Healthcare Providers & Services companies, Monsenso AS ranks worse than 446428.13% on this metric.
PE Ratio without NRI / 5-Year EBITDA Growth Rate*
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Monsenso AS's PE Ratio without NRI is 0.00. Monsenso AS's 5-Year EBITDA growth rate is 32.30%. Therefore, Monsenso AS's PEG Ratio for today is 0.00.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Monsenso AS's PEG Ratio or its related term are showing as below:
OCSE:MONSO's PEG Ratio is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 1.39 * Ranked among companies with meaningful PEG Ratio only.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Monsenso AS (OCSE:MONSO) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Monsenso AS PEG Ratio Related Terms
Monsenso AS PEG Ratio Historical Data
* Premium members only.
The historical data trend for Monsenso AS's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:MONSO vs VEEV, BTSG, TEM: PEG Ratio Comparison
For the Health Information Services subindustry, Monsenso AS's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monsenso AS PEG Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Monsenso AS's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Monsenso AS's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Monsenso AS (OCSE:MONSO) has a PEG Ratio of 0.00 as of Jul. 13, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Monsenso AS and its competitors. According to the industry distribution chart, Monsenso AS ranks #999999 out of 224 companies in the Healthcare Providers & Services industry.
Is Monsenso AS's PEG Ratio too high?
Monsenso AS's current PEG Ratio is 0.00. Based on the distribution chart, Monsenso AS ranks #999999 out of 224 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Monsenso AS has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Monsenso AS's PEG Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Monsenso AS ranks #999999 out of 224 companies for PEG Ratio. This places Monsenso AS in the lower half of its industry. The industry median PEG Ratio is 1.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Healthcare Providers & Services company?
The median PEG Ratio among Healthcare Providers & Services companies is 1.39, based on 224 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Monsenso AS and its competitors. For the Healthcare Providers & Services industry, the median PEG Ratio is 1.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monsenso AS's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monsenso AS stock overvalued right now?
Based on GuruFocus' analysis, Monsenso AS (OCSE:MONSO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.15, compared to a current price of kr0.30 — trading 100% above its estimated fair value. The current PEG Ratio is 0.00. Monsenso AS's overall GF Score™ is 29/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Monsenso AS (OCSE:MONSO), the current PEG Ratio is 0.00 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Monsenso AS (OCSE:MONSO) Overvalued in 2026?
Based on GuruFocus' analysis, Monsenso AS stock appears to be overvalued.
The current stock price of kr0.30 is trading 100% above its estimated GF Value™ of kr0.15.
GuruFocus considers Monsenso AS to be Significantly Overvalued.
Key valuation signals for OCSE:MONSO:
PEG Ratio: 0.00
GF Value™: kr0.15 vs. price of kr0.30 (100% above fair value)
No single metric tells the full story. See the OCSE:MONSO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Monsenso AS is a mobile mental health company. It technology company offering a digital health solution used for decentralized trials, remote patient monitoring, and treatment support. The company's mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data, and the solution helps optimise the treatment and gives a detailed overview of an individual's health through the collection of outcome, adherence, and behavioral data.
29GF Score
Get the complete analysis for OCSE:MONSO
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:MONSO has been successfully added to your 
